Endotoxin-stimulated immune response to modified lymphoma cells.
Bacterial endotoxin was administered with iodoacetamide-modified P1798 lymphoma cells to immunize syngenic BALB/cJ mice against this lymphoma to which they are naturally unresponsive. Three or four vaccinations with endotoxin (6.6 mug/injection) alone or the modified cells alone did not produce host resistance. A significant number (30 percent) of mice receiving both endotoxin and modified cells rejected a subsequent implant of viable tumor cells. Even those mice having progressive tumor growth exhibited prolonged survival. High doses of endotoxin given with the modified P1798 cells caused 70-75 percent of the mice to reject the tumor implants. When resistance developed, antibodies reacting with tumor cell membrane were demonstrable. These results indicate that B-lymphocyte stimulators can produce an effective immune response against lymphoma cells.[1]References
- Endotoxin-stimulated immune response to modified lymphoma cells. Prager, M.D., Ludden, C.M., Mandy, W.J., Allison, J.P., Kitto, G.B. J. Natl. Cancer Inst. (1975) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
